Evaluating outcomes in gastric cancer patients before and after a Tumor Board implementation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to compare surgical and oncologic outcomes in gastric cancer patients before and after the establishment of a Multidisciplinary Tumor Board at Fondazione Policlinico Gemelli. It will assess the Textbook Outcome (TO) and Textbook Oncological Outcome (TOO) of patients undergoing surgical treatment with curative intent. The study will analyze data from 2018 to the present to evaluate the impact of the Tumor Board on patient outcomes, including treatment allocation and adherence to guidelines. The hypothesis is that the implementation of the Tumor Board will lead to improved outcomes for gastric cancer patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* pathology-confirmed diagnosis of gastric adenocarcinoma
* age 18 years or older
* surgical candidates with curative intent

Exclusion Criteria:

* Endoscopic Mucosal Resection (EMR) or Endoscopic Submucosal Dissection (ESD)
* previous EMR or ESD (salvage surgery)
* histologies other than adenocarcinoma (no squamous cell carcinomas, GISTs, sarcomas, lymphomas, etc)
* unsufficient staging (unclear clinical stage at diagnosis)
* emergency presentation (obstrucetd, significantly bleeding, perforated gastric cancer)
* synchronous tumors affecting survival
* pregnant patients
* age \<18years

Where it's running

• Fondazione Policlinico Universitario Agostino Gemelli IRCCS
  Rome, It, Italy Recruiting

Study contacts

• Principal investigator: Alberto Biondi, Prof. — Fondazione Policlinico Agostino Gemelli IRCCS
• Study coordinator: Laura Antolino, MD, PhD
• Email: laura.antolino@gmail.com
• Phone: +393470409876

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Perioperative biomarker monitoring to spot complications after colorectal and gastric cancer surgery

  This randomized trial tests whether checking inflammatory and metabolic biomarkers during the perioperative period helps detect postoperative problems early in adults having colorectal or gastric cancer surgery.

  Recruiting Bucharest Emergency Hospital · Bucharest, Bucharest · NCT07881133

• Lenvatinib with nivolumab and chemotherapy for metastatic gastric cancer with malignant ascites

  This trial tests whether adding lenvatinib to nivolumab plus chemotherapy helps people with metastatic gastric or gastroesophageal junction adenocarcinoma who have peritoneal metastases and significant malignant ascites.

  Recruiting Phase 1/2 Asan Medical Center · Seoul · NCT07149090

• 18F-FAPI PET/CT and laparoscopy for staging advanced stomach cancer

  This trial tests whether an 18F-FAPI PET/CT scan, used with laparoscopy, can better find spread of advanced stomach cancer and help doctors avoid unnecessary surgery.

  Recruiting Phase 2/3 Leiden University Medical Center · Almelo and 9 other locations · NCT07018661

• Neoadjuvant zolbetuximab with docetaxel, oxaliplatin and S-1 for locally advanced stomach cancer

  This study will test whether adding zolbetuximab to docetaxel, oxaliplatin, and S-1 before surgery helps people with locally advanced, CLDN18.2-positive stomach cancer shrink tumors and have better outcomes.

  Recruiting at 2 sites Phase 1/2 Asan Medical Center · Seoul and 1 other locations · NCT06732856

• Combining radiotherapy and immunotherapy for limited metastatic gastric cancer

  This study is testing a new treatment that combines radiation, chemotherapy, and immunotherapy to see if it can help people with limited metastatic gastric cancer live longer and improve their health.

  Recruiting Phase 2 Fudan University · Shanghai · NCT06121700

• Combination of Trastuzumab Deruxtecan and Afatinib for HER2-low Advanced Gastric Cancer

  This study is testing a new combination of two drugs, Trastuzumab Deruxtecan and Afatinib, to see if it can help people with HER2-low advanced gastric cancer who don’t have many treatment choices.

  Recruiting Phase 1/2 Samsung Medical Center · Seoul · NCT06085755

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.